23. Dicaffeoyltartaric Acid and Dicaffeoylquinic Acid HIV Integrase Inhibitors

  1. Nouri Neamati
  1. David C. Crosby and
  2. W. Edward Robinson Jr.

Published Online: 28 SEP 2011

DOI: 10.1002/9781118015377.ch23

HIV-1 Integrase: Mechanism and Inhibitor Design

HIV-1 Integrase: Mechanism and Inhibitor Design

How to Cite

Crosby, D. C. and Robinson, W. E. (2011) Dicaffeoyltartaric Acid and Dicaffeoylquinic Acid HIV Integrase Inhibitors, in HIV-1 Integrase: Mechanism and Inhibitor Design (ed N. Neamati), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9781118015377.ch23

Editor Information

  1. Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, Los Angeles, California, USA

Author Information

  1. Department of Pathology and Laboratory Medicine, University of California, Irvine, California, USA

Publication History

  1. Published Online: 28 SEP 2011
  2. Published Print: 9 SEP 2011

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470184745

Online ISBN: 9781118015377

SEARCH

Keywords:

  • dicaffeoyltartaric acid, and HIV IN inhibitors;
  • L-CA, antiviral and anti-IN activity;
  • L-CA, partner antiretroviral therapy

Summary

This chapter contains sections titled:

  • Introduction

  • Discovery

  • Characterization of L-CA as a Selective IN Inhibitor

  • Controversy Surrounding In Vivo Site of Action For L-CA

  • Mechanisms of Viral Resistance

  • Stucture-Activity Relationship Studies

  • L-CA in Combination with Reverse Transcriptase and Protease Inhibitors

  • Summary

  • Acknowledgments

  • References